BenevolentAI SPAC Presentation Deck
Successful collaboration with
AstraZeneca
Multi-year Target-ID collaboration to find novel targets for
Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis
Separate data environment established to integrate AZ data into
a bespoke Knowledge Graph
BenevolentAl and AstraZeneca teams working in close
collaboration to explore, identify and validate targets
Key milestone reached Jan 2021: AZ took first novel Al-generated
target for CKD into their drug portfolio, with further targets to
follow
Deal structure of upfront license fee, milestone payments
And downstream royalties
AstraZeneca
B
"The vast amount of data available to
research scientists is growing exponentially
each year. By combining AstraZeneca's
disease area expertise and large, diverse
datasets with BenevolentAl's leading Al
and machine learning capabilities, we can
unlock the potential of this wealth of data
to improve our understanding of complex
disease biology and identify new targets
that could treat debilitating diseases."
Mene Pangalos
EVP & President, R&D BioPharmaceuticals,
AstraZeneca
COLLABORATION VIDEOView entire presentation